Race comparisons in patients with cardiac sarcoidosis: Insights from the cardiac sarcoidosis consortium

Authors

Angkawipa Trongtorsak, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond (A.T., J.D.L.R.M., K.A.E., J.K.).
Junior De La Rosa Martinez, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond (A.T., J.D.L.R.M., K.A.E., J.K.).
Thomas C. Crawford, Department of Cardiology, University of Michigan Health System, Ann Arbor (T.C.C., F.M.B., X.G., E.P.).
Frank M. Bogun, Department of Cardiology, University of Michigan Health System, Ann Arbor (T.C.C., F.M.B., X.G., E.P.).
Xiaokui Gu, Department of Cardiology, University of Michigan Health System, Ann Arbor (T.C.C., F.M.B., X.G., E.P.).
Eric Purroll, Department of Cardiology, University of Michigan Health System, Ann Arbor (T.C.C., F.M.B., X.G., E.P.).
Kenneth A. Ellenbogen, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond (A.T., J.D.L.R.M., K.A.E., J.K.).
Alexandru B. Chicos, Division of Cardiology, Department of Medicine, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University, Chicago, IL (A.B.C.).
Henri Roukoz, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis (H.R.).
Peter J. Zimetbaum, Beth Israel Deaconess Medical Center, Boston, MA (P.J.Z.).
Steven J. Kalbfleisch, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus (S.J.K.).
Francis D. Murgatroyd, Department of Cardiology, King's College Hospital NHS Foundation Trust London, United Kingdom (F.D.M., K.M.).
David A. Steckman, Division of Cardiology, Albany Medical College, NY. (D.A.S., M.T.).
Lynda E. Rosenfeld, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (L.E.R.).
Kyoko Soejima, Kyorin University School of Medicine, Tokyo, Japan (K.S.).
Adarsh K. Bhan, Advocate Health - MidwestFollow
Vasanth Vedantham, University of California-San Francisco (V.V., D.G.R.).
Timm-Michael L. Dickfeld, University of Maryland School of Medicine, Baltimore (T.-M.L.D.).
David B. De Lurgio, Emory University, St. Joseph's Hospital, Atlanta, GA (D.B.D.L.).
Pyotr G. Platonov, Department of Cardiology, Institution for Clinical Sciences, Lund University, Sweden (P.G.P.).
et al

Recommended Citation

Trongtorsak A, De La Rosa Martinez J, Crawford TC, et al. Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium. Circ Arrhythm Electrophysiol. 2025;18(7):e013670. doi:10.1161/CIRCEP.124.013670

Affiliations

Advocate Christ Medical Center

Abstract

Background: Differences in cardiac sarcoidosis between racial groups remain understudied. Therefore, this study aims to explore race differences in patients with cardiac sarcoidosis.

Methods: We analyzed data from the Cardiac Sarcoidosis Consortium, an international registry including over 25 centers. The primary clinical outcome was a composite end point of all-cause mortality, left ventricular assist device implantation, heart transplantation, or implantable cardioverter defibrillator therapy.

Results: A total of 619 patients were included in the study (362 White, 193 Black, and 64 other races). Black patients were diagnosed with cardiac sarcoidosis at a younger age (50.5±11.8 versus 53.7±10.5 years old; P=0.010) compared with White patients. Left ventricular ejection fraction was significantly lower in Black patients (44.6±15.4 versus 48.3±14.0; P=0.008). In addition, extracardiac involvement in the lungs (80.3% versus 72.7%; P=0.046), skin (22.8% versus 12.4%; p=0.002), and eyes (13.5% versus 5.5%; P=0.001) was more prevalent in Black patients. Patients had significantly higher rates of hypertension (69.9% versus 50.6%; PPPPPP=0.4), glucocorticoid-sparing (53.4% versus 59.9%; P=0.14), and implantable cardioverter defibrillator or cardiac resynchronization implantation (75.6% versus 73.8%; P=0.63), were similar. No significant differences were found in the primary outcome (29.5% in Black versus 28.5% in White; P=0.79). Subgroup analysis of the primary outcome also revealed no significant differences in both the left ventricular ejection fraction >35% group (24.1% in Black versus 25.9% in White; P=0.72) and the left ventricular ejection fraction ≤35% group (51% versus 42.5%; P=0.35).

Conclusions: Black patients with cardiac sarcoidosis exhibited significantly higher rates of lung, skin, and eye involvement and comorbidities, but had similar cardiac clinical outcomes and all-cause mortality compared with White patients. Nonetheless, ascertainment bias cannot be excluded.

Type

Article

PubMed ID

40557494